NAFDAC hints on preparedness to roll out malaria vaccine clinical trial
By Ibiyemi Mathew
The National Agency for Food and Drug Administration and Control (NAFDAC) has revealed that it is prepared to begin Malaria Vaccine Clinical trials in its resolve to exterminate malaria scourge in Nigeria.
The Director General of NAFDAC, Prof. Mojisola Adeyeye, dropped the hint on Friday at the Pharmacovigilance Inspection interactive session with Pharma Stakeholders in Lagos.
During the inspection, the NAFDAC boss explained that the pharmaceutical industry must put structures in place to ensure adequate monitoring of their products throughout the supply chain.
She added that they must have strategies, goals, and clear objectives that will ensure the safe use of their products.
In a statement by the NAFDAC Resident Media Consultant, Sayo Akintola, on Sunday, Prof Adeyeye pointed out that the MAHs must as a matter of importance train and further engage all relevant stakeholders along their supply chain on the need for pharmacovigilance and use of relevant reporting platforms for reporting ADRs/AEFIs to the Agency.
According to her, the sustained safety of medical products in Nigeria lies on a vast array of stakeholders and it has become imperative to continually improve on pharmacovigilance processes for safety monitoring.
She also noted that the various public health programs involved in the importation of medical products for use in their respective programmes are regarded as marketing authorisation holders for their products and therefore encouraged them to establish and identify key personnel that will coordinate the activities of pharmacovigilance within their programmes.
She however noted that the six pharmacovigilance centres established across the six geopolitical zones of the country will be strengthened further to serve as convergence centres from the States to the Centre: but most importantly from the communities to the States to the Centres. She said those centres that have been approved should also be involved, as she vowed to take charge of strengthening them personally.
She explained that community pharmacists are strategic in this call because they reach the populace more than any other sector with impressive records. She noted that since community pharmacists are also involved with immunisation delivery services, it has become imperative that their pharmacovigilance system should be inspected to ensure compliance with PV regulations and guidelines.
Going down the memory lane, Prof. Adeyeye said NAFDAC since its inception had engaged in some level of activities towards ensuring the safe use of medical products in-country. She stated that in recent times, pharmacovigilance has been brought to the fore with the COVID-19 pandemic and the key role that the African Union smart safety surveillance (AU 3S) played in assuring safety of products used in the pandemic within the member countries including Nigeria.
The AU-3S programme, led by African Union Development Agency (AUDA-NEPAD), aims to create a sustainable continental safety monitoring system to improve the safety of priority medical products for patients across Africa. The AU3S coordinated surveillance system was piloted with the COVID-19 vaccines in the five member countries with the goal of future continent-wide safety surveillance of other medical products.
Prof Adeyeye further explained that the AU3S also provided platform for capacity building of Staff on various aspects of Pharmacovigilance, noting that this greatly contributed towards NAFDAC’s attainment of Maturity Level 3 (ML3) under the WHO global benchmarking system. “This means that we are now a stable, well-functioning and integrated regulatory system.”
Having achieved this feat, she said the Agency is now poised to delve into aspects of pharmacovigilance inspection which before now “we had not ventured into.”
She opined that Pharmacovigilance Inspections of Marketing Authorization Holders (MAHs) is a key aspect of Pharmacovigilance which cannot be ignored by any regulatory authority that has intentions of ensuring patient safety with use of medical products and attaining higher levels of maturity in its regulatory processes.
She disclosed that following the dismal outcome of the WHO first Benchmarking visit, she, and Pharmacist Ali started talking with The Gates Foundation, represented by Ms. RajLong at a conference in Abuja, stressing that she was the push to the improvement that had taken place.
She said the Agency got the digital tool, the Med Safety App launched in November 2021 to aid reporting, adding that “this instantly revolutionised what we were doing.” She said the ADR/AEFI reporting of pharmacovigilance improved 10 to 15 times because of the use of the digital tool.
‘’During the Pandemic we were meeting every two weeks with AU3s, reporting everything that was taking place in Nigeria. We also have the National Signal Detection Group that was meeting with other National Regulatory Agencies in their own different groups. NAFDAC/ Nigeria led the reporting of AEFIs because of the change that can take place in a particular Directorate.”
As pharmacists, she urged the stakeholders to think of the science that can lead to side effects, serious side effects and signals.
The National President of Community Pharmacists Association of Nigeria, Pharm. Wale Oladigbolu FPSN commended NAFDAC for the initiative, stressing that ‘’although PV is not new, with this new approach we know that we will be dealing with the public in a very scientific manner to protect their health.”
Describing drugs as very potent chemicals, Pharm Oladigbolu noted that if sent on an errand to go and cure, it could cause a damage in the process, stressing that ‘’we want to aggregate the number of damages they have caused over a period of time so that we can scientifically say that this drug is still delivering on promise, or this drug should be withdrawn.”
